Wake-up haul: an Ozempic moment for the brain

Summary

This The Intelligence episode links three evidence-led briefings: Shailesh Chitnis on orexin agonists as a possible post-GLP-1 drug excitement, Ethan Wu on Japan’s weak startup record, and Benjamin Sutherland on procrastination as self-regulatory failure. The drug segment is promising but explicitly early: Ovoperextone and narcolepsy supply the first use case, while depression, ADHD, and addiction remain future hopes. The Japan and procrastination segments treat social context as practical constraint: capital markets and status norms shape startup outcomes, while sleep, distraction, exercise, planning, and executive function shape delayed action.

Key Claims

• Orexin Agonists mimic orexin, a brain neuropeptide the episode describes as central to wakefulness and the boundary between sleep and waking.
• Ovoperextone, made by Takeda Pharmaceutical / 武田制药, is source-described as an FDA-approved narcolepsy drug, with Alkermes and Eli Lilly also working on orexin agonists.
• Eli Lilly’s purchase of Sentessa Pharmaceuticals is presented as evidence that large pharma sees orexin as commercially important.
• Emmanuel Mignot’s Stanford dog research is used as the discovery story linking narcolepsy to failure to respond to orexin.
• The episode compares the category to GLP-1 Agonists and Ozempic, but Shailesh Chitnis cautions that many plausible drug ideas fail before broad market use.
• Morgan Stanley is cited for an estimate that orexin medicines could generate almost $16 billion a year by 2035, compared with about $3 billion for current narcolepsy drugs.
• Ethan Wu says Japan has produced only six of roughly 1,400 global unicorns, despite postwar startup successes such as Sony, Honda / 本田, and SoftBank.
• The Japan segment makes Japanese Startup Exit Constraint a three-part problem: too little late-stage venture capital, low social status for entrepreneurship, and pressure to list too early.
• Global Entrepreneurship Monitor survey evidence is used to show low desirability of entrepreneurship in Japan compared with the global average.
• Tokyo Stock Exchange reform is presented as a possible correction: from 2030, growth-market firms unable to maintain a 10 billion yen market cap after five years may be delisted.
• Sakana AI is named as Japan’s most valuable unicorn and an AI tailwind, while the episode notes that Japan has not yet produced a decacorn.
• Benjamin Sutherland frames procrastination as Procrastination Self-Regulation Failure linked to lower income, delayed medical treatment, pain, lower self-esteem, and future depression.
• The episode treats Mental Contrasting With Implementation Intentions and Exercise Self-Mastery For Procrastination as stronger intervention candidates than diet associations, while medication evidence remains indirect and ADHD-specific.

Key Quotes

“Ozempic moment” - the episode’s framing for possible orexin expansion beyond narcolepsy.

“self-regulatory failure” - the research label used for procrastination.

“starting point rather than the end goal” - Yamaji Hiromi’s frame for healthier IPOs.

Connections

• The Intelligence, Economist Podcasts, Rosie Bloor, Shailesh Chitnis, Ethan Wu, and Benjamin Sutherland - show, publisher, host, and segment voices.
• Orexin Agonists, Narcolepsy Wake-Sleep Boundary, Ovoperextone, Takeda Pharmaceutical / 武田制药, Alkermes, Eli Lilly, Sentessa Pharmaceuticals, Emmanuel Mignot, Morgan Stanley, Food and Drug Administration, GLP-1 Agonists, and Ozempic - orexin, narcolepsy, drug-development, and GLP-1 analogy cluster.
• Japan, Sony, Honda / 本田, SoftBank, Japanese Startup Exit Constraint, Global Entrepreneurship Monitor, Tokyo Stock Exchange, Yamaji Hiromi, Sakana AI, Japanese Innovation Retreat / 日本创新退潮, Startup Ecosystem Optimism, and Youth Entrepreneurship - Japan startup ecosystem and public-market reform cluster.
• Procrastination Self-Regulation Failure, Mental Contrasting With Implementation Intentions, Exercise Self-Mastery For Procrastination, Perfectionism As Avoidance, and FocusFly / 专注飞机 - procrastination, planning, exercise, and attention-management cluster.

Contradictions

• No direct contradiction found.
• The source extends GLP-1 Agonists by analogy only; it does not claim orexin agonists already have GLP-1-scale evidence or breadth.
• The source extends Japanese Innovation Retreat / 日本创新退潮 with venture-capital and IPO-market mechanisms rather than replacing the earlier cultural and industrial-path-dependence account.
• The procrastination segment overlaps with Perfectionism As Avoidance but uses a different explanatory lens: measurable self-regulation, distraction, sleep, exercise, and health behavior rather than perfectionism alone.